Centro de Investigación de Medicina Aplicada (CIMA)
Centro / Instituto vinculado a la Universidad de Navarra
Hospital of the University of Pennsylvania
Filadelfia, Estados UnidosPublicaciones en colaboración con investigadores/as de Hospital of the University of Pennsylvania (9)
2023
-
Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)
Leukemia
-
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents
Blood, Vol. 141, Núm. 3, pp. 219-230
2022
-
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
Blood cancer journal, Vol. 12, Núm. 2, pp. 32
-
Mutant IDH Inhibits IFNg–TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma
Cancer Discovery, Vol. 12, Núm. 3, pp. 812-835
2017
-
Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody
Clinical Cancer Research, Vol. 23, Núm. 8, pp. 1929-1936
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
-
Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: A retrospective multicohort analysis
Journal of Clinical Oncology, Vol. 34, Núm. 21, pp. 2468-2477
2014
-
Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma
Cancer Cell, Vol. 25, Núm. 6, pp. 735-747
2009
-
Virus-Induced Unfolded Protein Response Attenuates Antiviral Defenses via Phosphorylation-Dependent Degradation of the Type I Interferon Receptor
Cell Host and Microbe, Vol. 5, Núm. 1, pp. 72-83